Prevention of schizophrenia

Expert Review of Neurotherapeutics

Volumn 10, Issue 7, 2010, Pages 1165-1174

  Tsuang, Ming T ^a,b   Stone, William S ^b   Auster, Tracey L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

duration of untreated psychosis; endophenotypes; liability syndromes; specialized programs; vulnerability to psychosis

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; RISPERIDONE; PSYCHOTROPIC AGENT;

BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; DISEASE PREDISPOSITION; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MENTAL FUNCTION; MOLECULAR BIOLOGY; NEUROIMAGING; PREGNANCY; PREGNANCY COMPLICATION; PSYCHOEDUCATION; PSYCHOPHARMACOLOGY; PSYCHOPHYSIOLOGY; PSYCHOSOCIAL DISORDER; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SOCIAL STATUS; BRAIN; EARLY DIAGNOSIS; PATHOLOGY; PSYCHOLOGY;

BRAIN; COGNITIVE THERAPY; EARLY DIAGNOSIS; HUMANS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77954206276     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.87     Document Type: Review

References (89)

1. Tsuang MT, Stone WS, Faraone SV. Schizophrenia: a review of genetic studies. Harv. Rev. Psychiatry 7, 185-207 (1999).
2. Hu TW. Perspectives: an international review of the national cost estimates of mental illness, 1990-2003. J. Ment. Health Policy Econ. 9, 3-13 (2006).
3. Wu EQ, Birnbaum HG, Shi L et al. The economic burden of schizophrenia in the United States in 2002. J. Clin. Psychiatry 66, 1122-1129 (2005).
4. Tsuang MT, Stone WS, Faraone SV. Towards reformulating the diagnosis of schizophrenia. Am. J. Psychiatry 147, 1041-1050 (2000).
5. Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 33, 21-32 (2007).
6. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160, 636-645 (2003).
7. Bilder RM. Phenomics: building scaffolds for biological hypotheses in the post-genomic era. Biol Psychiatry 63(5), 439-440 (2008).
8. Bassett AS, Marshall CR, Lionel AC, Chow EW, Scherer SW. Copy number variations and risk for schizophrenia in 22q11.2 deletion syndrome. Hum. Mol. Genet. 17(24), 4045-4053 (2008).
9. Bassett AS, Chow EW. Schizophrenia and 22q11.2 deletion syndrome. Curr. Psychiatry Rep. 10(2), 148-157 (2008).
10. Greenwood TA, Braff DL, Cadenhead KS et al. The Consortium on the Genetics of Schizophrenia (COGS): preliminary heritability analyses of endophenotypic measures for schizophrenia. Arch. Gen. Psychiatry 64, 1242-1250 (2007).
11. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv. Rev. Psychiatry 15, 245-258 (2009).
12. Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol. Psychiatry 52, 969-971 (2002).
13. Keefe RSE, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 633-647 (2007).
14. Swartz MS, Perkins DO, Stroup TS et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: fndings from the NIMH CATIE study. Am. J. Psychiatry 164, 428-436 (2007).
15. Yung AR, Killackey E, Hetrick SE et al. The prevention of schizophrenia. Int. Rev. Psychiatry 19(6), 633-646 (2007).
16. Gottesman, II, Hanson DR. Human development: biological and genetic processes. Annu. Rev. Psychol. 56, 263-286 (2005).
17. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in frst-episode psychosis really matter? Psychol. Med. 33(1), 97-110 (2003).
18. Keshavan MS, Amirsadri A. Early intervention in schizophrenia: current and future perspectives. Curr. Psychiatry Rep. 9(4), 325-328 (2007).
19. Cornblatt BA, Lencz T, Smith C, Auther A. Treatment of the schizophrenia prodrome. In: Recognition and Prevention of Major Mental and Substance Abuse Disorders. Tsuang MT, Stone WS, Lyons MJ (Eds). American Psychiatric Publishing, Inc., DC, USA, 159-185 (2007).
20. Cornblatt B, Lencz T, Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr. Res. 54(1-2), 177-186 (2002).
21. Brown KW, White T. Syndromes of chronic schizophrenia and some clinical correlates. Br. J. Psychiatry 161, 317-322 (1992).
22. Brown AS, Susser ES. Prenatal nutritional defciency and risk of adult schizophrenia. Schizoph. Bull. 1054-1063 (2008).
23. Kinney DK, Teixeira P, Hsu D et al Relation of schizophrenia to latitude, climate, fsh consumption, infant mortality and skin color: a role for prenatal vitamin d defciency and infections? Schizophr. Bull 35, 582-595 (2009).
24. Glatt SJ, Faraone SV, Tsuang MT. Genetic risk factors for mental disorders: General principles and state of the science. In: Recognition and Prevention of Major Mental and Substance Use Disorders. Tsuang MT, Stone WS, Lyons MJ (Eds). American Psychiatric Publishing, Inc., DC, USA, 3-20 (2007).
25. Tsuang MT, Stone WS, Johnston JM. Gene-environment interactions in mental disorders: a current view. In: The Impact of the Environment on Psychiatric Disorder. Freeman H, Stansfeld S (Eds). Routledge, London, UK, 27-51 (2008).
26. Mortensen PB, Pedersen CB, Westergaard T, Wohlfahrt J, Ewald H, Mors O. Effects of family history and place and season of birth on the risk of schizophrenia. N. Eng. J. Med. 340, 603-608 (1999).
27. Mortensen PB, Pedersen MG, Pedersen CB. Psychiatric family history and schizophrenia risk in Denmark: which mental disorders are relevant? Psychol. Med. 40, 201-210 (2010).
28. Dazzan P, Kravariti E, Fearon P, Murray RM. Is the development of schizophrenia predictable? In: Early Clinical Intervention and Prevention in Schizophrenia. Stone WS, Faraone SV, Tsuang MT (Eds). Humana Press, NJ, USA, 225-252 (2004).
29. Stone WS, Faraone SV, Seidman LJ, Olson EA, Tsuang MT. Searching for the liability to schizophrenia: concepts and methods underlying genetic high-risk studies of adolescents. J. Child Adolesc. Psychopharmacol. 15, 403-417 (2005).
30. Faraone SV, Doyle A. The nature and heritability of attention defcit hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am. 10, 299-316 (2001).
31. Hans SL, Auerbach JG, Auerbach AG, Marcus J. Development from birth to adolescence of children at-risk for schizophrenia. J. Child Adolesc. Psychopharmacol. 15(3), 384-394 (2005).
32. Hans SL, Auerbach JG, Asarnow JR, Styr B, Marcus J. Social adjustment of adolescents at risk for schizophrenia: the Jerusalem infant development study. J. Am. Acad. Child Adolesc. Psychiatry 39(11), 1406-1414 (2000).
33. Walker E, Lewine RJ. Prediction of adult-onset schizophrenia from childhood home movies of the parents. Am. J. Psychiatry 147(8), 1052-1056 (1990).
34. Schiffman J, Walker E, Ekstrom M, Schulsinger F, Sorensen H, Mednick S. Childhood videotaped social and neuromotor precursors of schizophrenia: a prospective investigation. Am. J. Psychiatry 161, 2021-2027 (2004).
35. Eack SM, Mermon DE, Montrose DM et al. Social cognition defcits among individuals at familial high risk for schizophrenia. Schizophr. Bull. DOI: 10.1093/schbul/sbp026 (2010) (Epub ahead of print).
36. Siira V, Wahlberg KE, Miettunen J, Tienari P, Laksy K. Differentiation of adoptees at high versus low genetic risk for schizophrenia by adjusted MMPI indices. Eur. Psychiatry 21(4), 245-250 (2006).
37. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 33(1), 69-94 (2007).
38. Takahashi S, Tanabe E, Yara K, Matsuura M, Matsushima E, Kojima T. Impairment of exploratory eye movement in schizophrenia patients and their siblings. Psychiatry Clin. Neurosci. 62(5), 487-493 (2008).
39. Calkins ME, Iacono WG, Curtis CE. Smooth pursuit and antisaccade performance evidence trait stability in schizophrenia patients and their relatives. Int. J. Psychophysiol. 49(2), 139-146 (2003).
40. Calkins ME, Iacono WG, Ones DS. Eye movement dysfunction in frst-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes. Brain Cogn. 68(3), 436-461 (2008).
41. Cannon TD. Abnormalities of brain structure and function in schizophrenia: implications for etiology and pathophysiology. Ann. Med. 28, 533-539 (1996).
42. Seidman LJ, Pantelis C, Keshavan MS et al. A review and a new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a MRI morphometric family study of the parahippocampal gyrus. Schizophr. Bull. 29, 803-808 (2003).
43. Keshavan MS, Montrose DM, Pierri JN et al. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: preliminary studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 21, 1285-1295 (1997).
44. Keshavan MS, Dick E, Mankowski I et al. Decreased left amygdala and hippocampal volumes in young offspring at risk for schizophrenia. Schizophr. Res. 58, 173-183 (2002)
45. MacDonald AW 3rd, Thermenos HW, Barch DM, Seidman LJ. Imaging genetic liability to schizophrenia: systematic review of FMRI studies of patients' nonpsychotic relatives. Schizophr. Bull. 35(6), 1142-1162 (2009).
46. Munoz Maniega S, Lymer GK, Bastin ME et al. A diffusion tensor MRI study of white matter integrity in subjects at high genetic risk of schizophrenia. Schizophr. Res. 106(2-3), 132-139 (2008).
47. 1H spectroscopy study. Schizophr. Res. 115(1), 88-93 (2009).
48. Modrego PJ. Depression in the prodromal phase of Alzheimer disease and the reverse causal hypothesis. Arch. Gen. Psychiatry 66(1), 107 (2009).
49. Geddes JR, Lawrie SM. Obstetric complications and schizophrenia: a meta-analysis. Br. J. Psychiatry 167(6), 786-793 (1995).
50. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am. J. Psychiatry 159(7), 1080-1092 (2002).
51. McGrath JJ. Gaining traction on the epidemiologic landscape of schizophrenia. Am. J. Epidemiol. 158, 301-304 (2003).
52. Gilbert AR, Montrose DM, Sahni SD, Diwadkar VA, Keshavan MS. Obstetric complications correlate with neurobehavioral and brain structural alterations in young relatives at risk for schizophrenia. Ann. NY Acad. Sci. 1008, 269-275 (2003).
53. Gur RE, Calkins ME, Gur RC et al. The Consortium on the Genetics of Schizophrenia (COGS): neurocognitive endophenotypes. Schizophr. Bull. 33, 49-68 (2007).
54. Kremen WS, Hoff AL. Neurocognitive defcits in the biological relatives of individuals with schizophrenia. In: Early Clinical Intervention and Prevention with Schizophrenia. Stone WS, Faraone SV, Tsuang MT (Eds). Humana Press, NJ, USA, 133-158 (2004).
55. Snitz BE, MacDonald III AW, Carter AS. Cognitive defcits in unaffected frst-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr. Bull. 32, 179-194 (2006).
56. Prasad KM, Sanders R, Sweeney J et al. Neurological abnormalities among offspring of persons with schizophrenia: relation to premorbid psychopathology. Schizophr. Res. 108(1-3), 163-169 (2009).
57. Kremen WS, Seidman LJ, Goldstein JM, Faraone SV, Tsuang MT. Systematized delusions and neuropsychological function in paranoid and nonparanoid schizophrenia. Schizophr. Res.12, 223-236 (1994).
58. Brewer WJ, Wood SJ, Phillips LJ et al. Generalized and specifc cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr. Bull. 32, 538-555 (2006).
59. Stone WS, Faraone SV, Seidman LJ, Olson EA, Tsuang MT. Searching for the liability to schizophrenia: concepts and methods underlying genetic high-risk studies of adolescents. J. Child Adolesc. Psychopharmacol. 15(3), 403-417 (2005).
60. Hill SK, Reilly JL, Harris MSH et al. A comparison of neuropsychological dysfunction in frst-episode psychosis patients with unipolar depression, bipolar disorder and schizophrenia. Schizophr. Res. 113, 167-175 (2009).
61. Asarnow RF, Neuchterlein KH, Subotnik KL et al. Neurocognitive impairments in nonpsychotic parents of children with schizophrenia and attention-defcit/hyperactivity disorder: the UCLA family study. Arch. Gen. Psychiatry 59, 1053-1060 (2002).
62. Toomey R, Faraone SV, Seidman LJ, Kremen WS, Pepple JR, Tsuang MT. Association of vulnerability markers in relatives of schizophrenic patients. Schizophr. Res. 31, 89-98 (1998).
63. Faraone SV, Kremen WS, Lyons MJ, Pepple JR, Seidman LJ, Tsuang MT. Diagnostic accuracy and linkage analysis: how useful are schizophrenia spectrum phenotypes? Am. J. Psychiatry 152, 1286-1290 (1995).
64. Kremen WS, Lyons MJ, Boake C et al. A discordant twin study of premorbid cognitive ability in schizophrenia. J. Clin. Exp. Neuropsychol. 28(2), 208-224 (2006).
65. Mrazek P, Haggerty R. Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. National Academy of Sciences, Institute of Medicine, DC, USA (1994).
66. Gottesman II, Shields J. Schizophrenia and Genetics: A Twin Study Vantage Point. Academic Press, NY, USA (1972).
67. Meehl PE. Schizotaxia, schizotypy, schizophrenia. Am. Psychol. 17, 827-838 (1962).
68. Meehl PE. Schizotaxia revisited. Arch. Gen. Psychiatry 46, 935-944 (1989).
69. Faraone SV, Green AI, Seidman LJ, Tsuang MT. 'Schizotaxia': clinical implications and new directions for research. Schizophr. Bull. 27, 1-18 (2001).
70. Tsuang MT, Stone WS, Seidman LJ et al. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biol. Psychiatry 41, 1412-1418 (1999).
71. Tsuang MT, Stone WS, Tarbox SI, Faraone SV. An integration of schizophrenia with schizotypy: identifcation of schizotaxia and implications for research on treatment and prevention. Schizophr. Res. 54(1-2), 169-175 (2002).
72. Stone WS, Faraone SV, Seidman LJ, Green AI, Wojcik JD, Tsuang MT. Concurrent validation of schizotaxia: a pilot study. Biol. Psychiatry 50(6), 434-440 (2001).
73. Simon AE, Roth B, Zmilacher S, Isler E, Umbricht D. Developing services for the early detection of psychosis: a critical consideration of the current state of the art. Eur. Child Adolesc. Psychiatry 16(2), 96-103 (2007).
74. Simon AE, Lester H, Tait L et al. The International Study on General Practitioners and Early Psychosis (IGPS). Schizophr. Res. 108(1-3), 182-190 (2009).
75. McGorry PD, Yung AR, Phillips LJ. The "close-in" or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr. Bull. 29(4), 771-790 (2003).
76. Phillips LJ, Yung AR, Yuen HP, Pantelis C, McGorry PD. Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. Am. J. Med. Genet. 114(8), 929-937 (2002).
77. Yung AR, Phillips LJ, Yuen HP et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 60(1), 21-32 (2003).
78. Cannon TD, Cadenhead KS, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 65, 28-37 (2008).
79. McGlashan TH, Zipursky RB, Perkins D et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr. Res. 61(1), 7-18 (2003). (Pubitemid 36332135)
80. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36(Suppl. 3), S162-S167 (2003).
81. Simon AE, Roth B, Zmilacher S, Isler E, Umbricht D. Developing services for the early detection of psychosis: a critical consideration of the current state of the art. Eur. Child Adolesc. Psychiatry 16, 96-103 (2007).
82. McGorry PD, Killackey EJ. Early intervention in psychosis: a new evidence based paradigm. Epidemiol. Psichiatr. Soc. 11(4), 237-247 (2002).
83. Walker EF, Cornblatt B, Addington J et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr. Res. 115, 50-57 (2009).
84. Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for psychosis. Schizophr Res. 116, 168-172 (2010).
85. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in frst-episode schizophrenia. Am. J. Psychiatry 149(9), 1183-1188 (1999).
86. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in frst-episode schizophrenia: a critical review and meta analysis. Am. J. Psychiatry 162, 1785-1804 (2005).
87. Farooq S, Large M, Nielssen O, Waheed W. The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: a systematic review and meta analysis. Schizophr. Res. 109, 15-23 (2009).
88. Friis S, Vaglum P, Haahr U et al. Effect of an early detection programme on duration of untreated psychosis: part of the Scandinavian TIPS study. Br. J. Psychiatry Suppl. 48, S29-S32 (2005). (Pubitemid 41139663)
89. Johannessen JO, Larsen TK, Joa I et al. Pathways to care for frst-episode psychosis in an early detection healthcare sector: part of the Scandinavian TIPS study. Br. J. Psychiatry Suppl. 48, S24-S28 (2005).